Lung Cancer News

A randomized phase 3 study designed to evaluate sugemalimab as treatment of stage III non-small cell lung cancer met its primary endpoint, according to the agent’s manufacturer.

The FDA approved amivantamab-vmjw for treatment of adults with non-small cell lung cancer who harbor EGFR exon 20 insertion mutations.

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

The FDA granted priority review to mobocertinib for treatment of certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

In a new study, researchers concluded there is “inconclusive evidence” of an association between less intensive diagnostic evaluations of lung nodules and more advanced stage at lung cancer diagnosis compared with guideline-recommended care.

Brendon Stiles, MD, has been named chief of thoracic surgery and surgical oncology at Montefiore Health System and Albert Einstein College of Medicine.

An exhaled breath test that uses high-pressure photon ionization time-of-flight mass spectrometry accurately identified patients with lung cancer, according to recent data in JAMA Network Open.

An intervention designed to keep family practitioners involved in the care of their patients with cancer had a “modest effect” on hospitalizations and ED visits 3 months after implementation, researchers wrote in Annals of Family Medicine.

Patients with anaplastic lymphoma kinase-mutant non-small cell lung cancer exhibited considerably higher risk for thromboembolism than those with EGFR-mutant or wild-type disease, study results showed.

Neoadjuvant combination immunotherapy improved outcomes for patients with operable non-small cell lung cancer, according to results of the randomized phase 2 NEOSTAR trial.